Psoriatic arthritis

Dermatologic Therapy

Volumn 23, Issue 2, 2010, Pages 123-136

  Wollina, Uwe ^a   Unger, Leonore ^a   Heinig, Birgit ^a   Kittner, Thomas ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Biologics; Dactylitis; DMARDS; Enthesitis; Psoriatic arthritis; Treatment; Uveitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; BASILIXIMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; GALIXIMAB; GOLIMUMAB; IMMUNOGLOBULIN ANTIBODY; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; ORTHOCLONE; PLACEBO; RITUXIMAB; SALAZOSULFAPYRIDINE; SIPILUZIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB;

ARTHRITIS; BLOOD; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; ENTHESITIS; ENTHESOPATHY; GRANULOMATOSIS; HIGH RISK PATIENT; HUMAN; IMAGE DISPLAY; IMMUNOPATHOGENESIS; INFECTION; JOINT RADIOGRAPHY; LIVER DISEASE; LOADING DRUG DOSE; LONG TERM CARE; LUPUS LIKE SYNDROME; MONARTHRITIS; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; TOXICITY; VASCULITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; MALE; PHYSICAL THERAPY MODALITIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950131577     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2010.01306.x     Document Type: Review

References (99)

1. Alibert JL. Precis theorique et practique sur les maladies de la peau, vol. 2. Paris : Caille & Ravier, 1818 : 21.
2. Bazin P. Theoriques et cliniquessur les affections cutanees de nature. Paris : Delahay Arthritique et Arthreux, 1869 : 154 161.
3. Moll JHM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973 : 3 : 55 78
4. Wollina U, Hein G, Knopf B. [Psoriasis and joint diseases. pathogenesis, clinics, diagnostic, and therapy of psoriatic osteoarthropathy]. Jena : G Fischer, 1996.
5. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis. Development of new criteria from a large international study. Arthritis Rheum 2006 : 54 : 2665 2673
6. D'Angelo S, Mennillo GA, Cutro MS, et al. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. J Rheumatol 2009 : 36 : 368 370.
7. Kleinert S, Feuchtenberger M, Kneitz C, Tony H-P. Psoriatic arthritis: clinical spectrum and diagnostic procedures. Clin Dermatol 2007 : 25 : 519 523.
8. Radtke MA, Reich K, Blome C, Rustenbach S, Augustin M. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 2009 : 23 : 683 691.
9. Tam LS, Leung YY, Li EK. Psoriatic arthritis in Asia. Rheumatology (Oxford) 2009 : 48 : 1473 1477.
10. Wilson FC, Icen M, Crowson CS, et al. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol 2009 : 36 : 361 367.
11. Hein G, Wollina U, Uhlemann C. Management of dermato-rheumatologic syndromes. Br J Rheumatology 1998 : 37 : 463.
12. Ho PY, Barton A, Worthington J, et al. Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis 2008 : 67 : 677 682.
13. Hein G, Knopf B, Wollina U, Abendroth K, Wessel G. [Psoriatic Osteopathy - results of histo-morphometric investigations]. Z Hautkrankh 1990 : 65 : 820 822.
14. FitzGerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 2009 : 11 : 214.
15. Robinson H, Kelly S, Pitzalis C. Basic synovial biology and immunopathology in psoriatic arthritis. J Rheumatol Suppl 2009 : 83 : 14 16.
16. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford) 2008 : 47 : 1635 1640.
17. Manni L, Lundeberg T, Fiorito S, Bonini S, Vigneti E, Aloe L. Nerve growth factor release by human synovial fibroblasts prior to and following exposure to tumor necrosis factor-alpha, interleukin-1 beta and cholecystokinin-8: the possible role of NGF in the inflammatory response. Clin Exp Rheumatol 2003 : 21 : 617 624.
18. Raychaudhuri SP, Raychaudhuri SK. The regulatory role of nerve growth factor and its receptor system in fibroblast-like synovial cells. Scand J Rheumatol 2009 : 38 : 207 215.
19. Karason A, Love TJ, Gudbjornsson B. A strong heritability of psoriatic arthritis over four generations-the Reykjavik Psoriatic Arthritis Study. Rheumatology (Oxford) 2009 : 48 : 1424 1428.
20. Wilson FC, Icen M, Crowson CS, McEvoy T, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 2009 : 61 : 233 239.
21. Girolomoni G, Gisondi P. Psoriasis and systemic inflammation: underdiagnosed enthesopathy. J Eur Acad Dermatol 2009 : 23 : 3 8.
22. Wollina U, Barta U. [Arthritis psoriatica - about the spectrum of cutaneous and joint manifestations]. Akt Rheumatol 2000 : 25 : 108 112.
23. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009 : 160 : 1040 1047.
24. Forrester DM. The 'cocktail sausage' digit. Arthritis Rheum 1983 : 26 : 664.
25. Benjamin M, McGonagle D. The enthesis organ concept and its relevance to the spondyloarthropathies. Adv Exp Med Biol 2009 : 649 : 57 70.
26. Sprott H, Hein G, Domke D, et al. [Enthesiopathies - diagnostics and therapy]. Z Ärztl Fortbild 1996 : 90 : 717 720.
27. McGonagle D, Benjamin M, Tan AL. The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all? Curr Opin Rheumatol 2009 : 21 : 340 347.
28. Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ. Psoriatic arthritis - outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994 : 33 : 834 839.
29. Wollina U, Barta U, Uhlemann C, Oelzner P, Hein G. [Nail changes in rheumatic diseases]. Hautarzt 1999 : 50 : 549 555.
30. Wollina U, Berger M, Karte K. Calculation of nail plate and matrix parameters by 20 MHz ultrasound in healthy volunteers and patients with skin disease. Skin Res Technol 2001 : 7 : 60 64.
31. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 2008 : 67 : 955 959.
32. Sturrock RD. Clinical utility of ultrasonography in spondyloarthropathies. Curr Rheumatol Rep 2009 : 11 : 317 320.
33. Weckbach S, Schewe S, Michaely HJ, Steffinger D, Reiser MF, Glaser C. Whole-body MR imaging in psoriatic arthritis: Additional value for therapeutic decision making. Eur J Radiol 2009 : in press.
34. Ostergaard M, McQueen F, Wiell C, et al. The OMERACT psoriatic arthritis magnetic resonance imaging scoring system (PsAMRIS): definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PsA hands. J Rheumatol 2009 : 36 : 1816 1824.
35. Guglielmi G, Scalzo G, Cascavilla A, et al. Imaging of the sacroiliac joint involvement in seronegative spondylarthropathies. Clin Rheumatol 2009 : 28 : 1007 1119.
36. Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001 : 19 : S17 S20.
37. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005 : 64 : ii74 ii77.
38. Kavanaugh AF, Ritchlin CT, and the GRAPPA Treatment Guideline Committee. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006 : 33 : 1417 1421.
39. Wollina U, Ständer K, Barta U. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis - short-time and long-term toxicity in 104 patients. Clin Rheumatol 2001 : 20 : 406 410.
40. Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984 : 27 : 376 381.
41. Abu-Shakra M, Gladman DD, Thorne JC, et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995 : 22 : 241 245.
42. Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol 2008 : 35 : 469 471.
43. Lie E, van der Heijde DM, Uhlig T, et al. The effectiveness and retention rates of methotrexate in psoriatic arthritis with methotrexate treated patients with rheumatoid arthritis as a reference population. Ann Rheum Dis 2009 : in press.
44. Kristensen LE, Gülfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008 : 67 : 364 369.
45. Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008 : 59 : 234 240.
46. Sarzi-Puttini P, Cazzola M, Panni B, et al. Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis. Rheumatol Int 2002 : 21 : 234.
47. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004 : 50 : 1939 1950.
48. Fraser AD, van Kuijk AWR, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005 : 64 : 859 864.
49. Antoni C, Dechant C, Lorenz H-M, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002 : 47 : 506 512.
50. Wollina U, Konrad H. Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody. J Eur Acad Dermatol Venereol 2002 : 16 : 127 129.
51. Xu Z, Vu T, Lee H, et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol 2009 : 49 : 1056 1070.
52. Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009 : 131 : 308 316.
53. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005 : 52 : 1227 1236.
54. van der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007 : 56 : 2698 2707.
55. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008 : 35 : 869 876.
56. Thomas VD, Yang FC, Kvedar JC. Biologics in psoriasis: a quick reference guide. J Am Acad Dermatol 2005 : 53 : 346 351.
57. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000 : 356 : 385 390.
58. Gottlieb AB, Kircik L, Eisen D, et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. J Dermatolog Treat 2006 : 17 : 343 352.
59. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006 : 33 : 712 721.
60. Mazzotta A, Esposito M, Schipani C, Chimenti S. Long-term experience with etanercept in psoriatic arthritis patients: A 3-year observational study. J Dermatolog Treat 2009 : 1 : 1 6.
61. Landewe R, Sterry W, Brocq O, et al. Similar efficacy of two etanercept regimens in treating joint symptoms in patients with both psoriasis and psoriatic arthritis (PRESTA Trial). Poster presented at the EULAR Congress, Copenhagen/ Denmark, June 10-13, 2009.
62. Kirkham B, Mease P, Williams T, et al. Improvement in enthesitis with etanercept therapy in patients with psoriasis and psoriatic arthritis (PRESTA Trial). Poster presented at the EULAR Congress, Copenhagen, Denmark, June 10-13, 2009.
63. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005 : 52 : 3279 3289.
64. Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT. Arthritis Rheum 2007 : 56 : 476 488.
65. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009 : 68 : 702 709.
66. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009 : 60 : 976 986.
67. Soriano ER, Rosa J. Update on the treatment of peripheral arthritis in psoriatic arthritis. Curr Rheumatol Rep 2009 : 11 : 270 277.
68. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-α inhibitor-induced psoriasis or psoriasiform exanthemata. First 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008 : 9 : 1 14.
69. Mousou A-E, Matekovits A, Dessinioti C, Antoniou C, Sfakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: A clinical review. J Am Acad Dermatol 2009 : 61 : 486 504.
70. Atteno M, Peluso R, Costa L, et al. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 2010 : in press.
71. Saad AA, Ashcroft DM, Watson KD, et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010 : in press.
72. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006 : 54 : 1638 1645.
73. Mease PJ, Reich K Alefacept in Psoriatic Arthritis Study Group. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2009 : 60 : 402 411.
74. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009 : 373 : 633 640.
75. Scheinfeld N. Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists. J Dermatolog Treat 2006 : 17 : 229 234.
76. Langley R, Roenigk HH, McCall C. Phase I results of intravenous MEDI-507, anti-T-cell monocolonal antibody, for the treatment of psoriasis. J Invest Dermatol 2001 : 117 : 817.
77. Gottlieb AB, Lebwohl M, Shirin S, et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 2000 : 43 : 595 604.
78. Owen CM, Harrsion PV. Successful treatment of severe psoriasis with basiliximab: an interleukin-2-receptor monoclonal antibody. Clin Exp Dermatol 2000 : 25 : 195 197.
79. Krueger JG, Walters IB, Miyazawa M, et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000 : 43 : 448 458.
80. Gottlieb AB, Kang S, Linden KG, et al. Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Immunol 2004 : 111 : 28 37.
81. Lange U. [Physical medicine in rheumatology and orthopedics]. Versicherungsmedizin 2009 : 61 : 10 14.
82. Maitland GD. [Manipulation of the Spine]. Berlin : Springer Verlag, 1991.
83. Adler SS, Beckers D, Buck M. PNF in Practice. Berlin : Springer Verlag, 2000.
84. Bowling RW, Erhard RE. Cyriax reexamined. Phys Ther 1994 : 74 : 1073 1075.
85. Lange U, Uhlemann Ch, Müller-Ladner U. Serial whole-body cryotherapy in the criostream for inflammatory rheumatic diseases. A pilot study. Med Klin 2008 : 103 : 383 388.
86. Krölling P, Kober L. [An automatized procedure for pressure-wave pain evaluation (Pressure Algometry) examplary demonstrated by the effects of ice packs and cold air]. Phys Rehab Kur Med 1994 : 4 : 173 176.
87. Schreiber U, Callies R. [What needs to be considered in cold air therapy] Phys Ther 1993 : 14 : 825 829.
88. Strunk J, Strube K, Klingenberger P, Müller-Ladner U, Lange U. Two- and three-dimensional Doppler sonographic evaluation of the effect of local cryotherapy on synovial perfusion in wrist arthritis. Rheumatology (Oxford) 2006 : 45 : 637 640.
89. Uhlemann C. [Pain modification in rheumatic diseases using different frequency applications of ultrasound]. Z Rheumatol 1993 : 52 : 236 240.
90. Rosenstein ED. Topical agents in the treatment of rheumatic disorders. Rheum Dis Clin North Am 1999 : 25 : 899 918, viii.
91. Bossert FP, Vogedes K. [Electrotherapy, Light- and Radiation-Therapy]. München : Urban & Fischer, 2003.
92. Mustur D, Vujasinović-Stupar N, Ille T. [Influence of physical treatment on disease activity and health status of patients with chronic arthritis]. Srp Arh Celok Lek 2008 : 136 : 104 109.
93. Chen CJ, Yu HS. Acupuncture, electrostimulation, and reflex therapy in dermatology. Dermatol Ther 2003 : 16 : 87 92.
94. Walker UA, Uhl M, Weiner SM, et al. Analgetic and disease modifying effects of interferential current in psoriatic arthritis. Rheumatol Int 2006 : 26 : 904 907.
95. Smolenski U. [Differentiation of Ultrasound and Short Waves for High-frequency Thermotherapy]. Thesis, Friedrich-Schiller-University Jena, 1990.
96. Moyer CA, Rounds J, Hannum JW. A meta-analysis of massage therapy research. Psychol Bull 2004 : 130 : 3 18.
97. Furlan AD, Brosseau L, Imamura M, Irvin E. Massage for low-back pain: a systematic review within the framework of the Cochrane Collaboration Back Review Group. Spine 2002 : 27 : 1896 1910.
98. Falkenbach A, Kovacs J, Franke A, Jörgens K, Ammer K. Radon therapy for the treatment of rheumatic diseases - review and meta-analysis of controlled clinical trials. Rheumatol Int 2005 : 25 : 205 210.
99. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009 : 68 : 1387 1394.